More than 30,000 people develop pancreatic adeno-carcinoma each year in the United
States, and almost all are expected to die from the disease. 1 The 5-year survival rate is 5 …

Recently, several decoy molecules belonging to tumor necrosis factor receptor superfamily
(TNFRSF) have been identified, including decoy receptor 1 (DcR1), decoy receptor 2 …

Background and aims: Emerging evidence suggests that highly treatment-resistant tumour-
initiating cells (TICs) play a central role in the pathogenesis of pancreatic cancer. Tumour …

Small cell lung cancer cell lines were resistant to FasL and TRAIL-induced apoptosis, which
could be explained by an absence of Fas and TRAIL-R1 mRNA expression and a deficiency …

Palliative chemotherapy with gemcitabine, a common mode of treatment of pancreatic
cancer, has little influence on patients' survival. We investigated the impact of anti‐apoptotic …

The understanding of the regulation of apoptosis and necrosis, the two principal cell death
pathways, is becoming exceedingly important in investigations of the pathogenesis and …

Somatostatin receptor subtype 2 (sst2) gene expression is lost in 90% of human pancreatic
adenocarcinomas. We previously demonstrated that stable sst2 transfection of human …

Although it displays promising activity in other tumor models, the effects of tumor necrosis
factor–related apoptosis-inducing ligand (TRAIL) on human pancreatic cancer cells have not …

Bioluminescence imaging (BLI) has shown to be crucial for monitoring in vivo biological
processes. So far, only dual bioluminescence imaging using firefly (Fluc) and Renilla or …

Overexpression of cellular FLICE-like inhibitory protein (cFLIP) is reported to confer
chemoresistance in pancreatic cancer (PaC) cells. This study was designed to investigate …